[New AMM: Nivolumab as an adjuvant for oesophageal and gastroesophageal junction cancer]

Julie Chartier; Clélia Coutzac

doi:10.1016/j.bulcan.2021.11.018

[New AMM: Nivolumab as an adjuvant for oesophageal and gastroesophageal junction cancer]

Bull Cancer. 2022 Apr;109(4):389-390. doi: 10.1016/j.bulcan.2021.11.018. Epub 2022 Feb 11.

[Article in French]

Authors

Julie Chartier¹, Clélia Coutzac²

Affiliations

¹ Hôpital Cochin, département d'oncologie médicale, 123, boulevard de Port Royal, 75014 Paris, France. Electronic address: jchartier@laposte.net.
² Centre Léon-Bérard, département d'oncologie médicale, 28, rue Laënnec, 69008 Lyon, France.

PMID: 35164916
DOI: 10.1016/j.bulcan.2021.11.018

No abstract available

Keywords: Cancer de l’œsophage et de la jonction œsogastrique; Esophageal and gastroesophageal junction cancer; Immune checkpoint inhibitor; Inhibiteurs de point de contrôle immunologique; Nivolumab; PD-1.

Publication types

Letter

MeSH terms

Esophageal Neoplasms* / drug therapy
Esophagogastric Junction
Humans
Nivolumab / therapeutic use
Stomach Neoplasms* / drug therapy

Substances

Nivolumab